Unlike the effort to decode the human genome, or the project to put a man on the moon, the mapping of the human brain is a fuzzy endeavor, with no obvious milestones along the way.
But the new trials by Millennium and Abbott stand as a valuable test of whether the money poured into genomics firms--not to mention the billions of dollars spent mapping the human genome--was really well spent.